Drug Profile
DRGT 31
Alternative Names: DRGT-31; Thrombin inhibitor - Tavanta TherapeuticsLatest Information Update: 28 Jun 2021
Price :
$50
*
At a glance
- Originator Druggability Technologies
- Developer Tavanta Therapeutics
- Class Anticoagulants; Antithrombins
- Mechanism of Action Thrombin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Haematological disorders
Most Recent Events
- 28 Jun 2021 No recent reports of development identified for preclinical development in Haematological-disorders in Hungary
- 01 Sep 2020 Druggability Technologies is now called Tavanta Therapeutics
- 15 May 2017 Preclinical trials in Haematological disorders in Hungary (Druggability Technologies pipeline, May 2017)